(Q53391458)

English

The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19494837%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19494837%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19494837%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

author name string

S Deleu

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19494837%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

M Lemaire

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19494837%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

J Arts

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19494837%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

E Van Valckenborgh

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19494837%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

P King

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19494837%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

I Vande Broek

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19494837%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

H De Raeve

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19494837%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

B Van Camp

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19494837%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

P Croucher

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19494837%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

K Vanderkerken

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19494837%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

publication date

4 June 2009

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19494837%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19494837%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

23

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19494837%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19494837%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

1894-1903

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19494837%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

https://scigraph.springernature.com/pub.10.1038/leu.2009.121

0 references

Specific roles for the PI3K and the MEK-ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

Bone marrow angiogenesis in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

Bone markers in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

Improved survival in multiple myeloma and the impact of novel therapies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

Single versus double autologous stem-cell transplantation for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

New drugs for myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

Anticancer activities of histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

Histone deacetylases: target enzymes for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

Valproic acid inhibits angiogenesis in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

Effects of short chain fatty acid, sodium butyrate, on osteoblastic cells and osteoclastic cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

Inhibition of histone acetylation as a tool in bone tissue engineering.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

Trichostatin A-mediated upregulation of p21(WAF1) contributes to osteoclast apoptosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

Molecular sequelae of histone deacetylase inhibition in human malignant B cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

Multiple myeloma biology: lessons from the 5TMM models

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

The 5TMM series: a useful in vivo mouse model of human multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

Murine 5T multiple myeloma cells induce angiogenesis in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

Proteomic analysis of MOLT-4 cells treated by valproic acid

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

Homing of the myeloma cell clone

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

Follow-up of bone lesions in an experimental multiple myeloma mouse model: description of an in vivo technique using radiography dedicated for mammography

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

Histone deacetylase inhibitors: biology and mechanism of action

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-beta production

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

Bortezomib inhibits human osteoclastogenesis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

Myeloma bone disease and proteasome inhibition therapies.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

Modulation of angiogenesis-related protein synthesis by valproic acid

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

Enhancing the anti-angiogenic action of histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

21 January 2018

Multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

7 January 2021

based on heuristic

inferred from DOI database lookup

Angiogenesis in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

7 January 2021

based on heuristic

inferred from DOI database lookup

Multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

7 January 2021

based on heuristic

inferred from DOI database lookup

Sodium butyrate activates ERK to regulate differentiation of mesenchymal stem cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

7 January 2021

based on heuristic

inferred from DOI database lookup

Upregulation of matrix metalloproteinase-9 in murine 5T33 multiple myeloma cells by interaction with bone marrow endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

7 January 2021

based on heuristic

inferred from DOI database lookup

JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

7 January 2021

based on heuristic

inferred from DOI database lookup

The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

7 January 2021

based on heuristic

inferred from DOI database lookup

The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.121

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53391458&oldid=1456799282"